Keros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Update

Keros Therapeutics, Inc. (NASDAQ:KROS) was the recipient of a significant increase in short interest in July. As of July 31st, there was short interest totalling 3,170,000 shares, an increase of 10.5% from the July 15th total of 2,870,000 shares. Based on an average daily volume of 343,600 shares, the days-to-cover ratio is presently 9.2 days.

Insider Buying and Selling at Keros Therapeutics

In other news, Director Carl L. Gordon sold 250,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $44.01, for a total transaction of $11,002,500.00. Following the sale, the director now owns 119,522 shares in the company, valued at approximately $5,260,163.22. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 22.90% of the company’s stock.

Institutional Trading of Keros Therapeutics

Large investors have recently made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. bought a new stake in Keros Therapeutics during the second quarter worth $128,000. Ameritas Investment Partners Inc. boosted its stake in shares of Keros Therapeutics by 14.5% in the 1st quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock valued at $169,000 after purchasing an additional 324 shares in the last quarter. Quest Partners LLC increased its position in Keros Therapeutics by 23,945.0% during the 2nd quarter. Quest Partners LLC now owns 4,809 shares of the company’s stock worth $220,000 after purchasing an additional 4,789 shares in the last quarter. XTX Topco Ltd bought a new position in Keros Therapeutics in the 2nd quarter valued at approximately $228,000. Finally, Arizona State Retirement System acquired a new stake in Keros Therapeutics in the fourth quarter valued at approximately $231,000. Institutional investors and hedge funds own 71.56% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on KROS shares. Truist Financial reaffirmed a “buy” rating and issued a $100.00 target price on shares of Keros Therapeutics in a report on Tuesday, June 18th. HC Wainwright reiterated a “buy” rating and issued a $100.00 price objective on shares of Keros Therapeutics in a report on Tuesday, June 18th. Finally, Oppenheimer began coverage on shares of Keros Therapeutics in a research note on Tuesday, June 25th. They issued an “outperform” rating and a $102.00 price target on the stock. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $92.17.

Keros Therapeutics Stock Performance

Shares of KROS stock traded down $0.50 during trading on Friday, hitting $45.54. The company had a trading volume of 265,099 shares, compared to its average volume of 379,065. The firm has a market capitalization of $1.64 billion, a P/E ratio of -8.84 and a beta of 1.23. Keros Therapeutics has a one year low of $27.02 and a one year high of $73.00. The stock’s 50-day moving average price is $46.84 and its 200 day moving average price is $54.69.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Wednesday, August 7th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.02). The firm had revenue of $0.04 million during the quarter. During the same quarter last year, the company posted ($1.27) EPS. On average, research analysts anticipate that Keros Therapeutics will post -4.8 earnings per share for the current fiscal year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.